ICO
Closed:
Seeking Druggable Targets in Progressive Fibrosing Interstitial Lung Disease or Pulmonary Hypertension
Johnson & Johnson, a global pharmaceutical company with cutting-edge capabilities in drug development and a history of successful academic collaborations, wishes to identify druggable targets in progressive fibrosing interstitial lung disease (PF‑ILD), idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH).
Research Interests
1. IPF/PF-ILDs
- Opportunities that offer the potential for clinical translation
- Mechanism of actions that reduce fibrosis by targeting TGF‑b signalling without the risk of inflammation, target activation, function of ...
Opportunity types being sought:
-
Spinout Company
-
Research Project
-
Centre of Excellence
-
Academic Researcher
-
Technology
To see the full details and submit your response please register now.
Benefits of registration:
- Receive updates on the latest industry calls
- Quickly and easily respond to calls via your dashboard
- Build your academic profile
Opportunity types being sought:
-
Spinout Company
-
Research Project
-
Centre of Excellence
-
Academic Researcher
-
Technology
Powered By
An online matchmaking platform for university-industry collaboration. Learn More
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.